| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00305162 Details | 2014-05-08 Interventional | 3 | [1 Refs] | 8882 | Cangrelor Clopidogrel Acute Coronary … Infarction Myocardial Infa… Acute Coronary … Myocardial Infa… | Insufficient evidence of the clinical effectiveness of cangrelor Discontinued per prespecified stopping rules after the 70% interim analyses was conducted indicating the trial was not likely to meet the goal of demonstrating superiority to clopidogrel administered as usual care. No safety issues were identified. | ||
| NCT00852059 Details | 2014-05-07 Interventional | 4 | 32 | Methylphenidate Attention Defic… ADHD | Diffculties to recruit anticipated study size, now analysis - | |||
| NCT00784836 Details | 2014-05-07 Interventional | 3 | 3 | Interferon beta… Interferon-beta Interferons Multiple Sclero… Sclerosis | Terminated early by Sponsor for business reasons unrelated to safety. Early termination with partial data from 3 subjects, therefore, no statistical analysis performed. | |||
| NCT00406575 Details | 2014-05-07 Interventional | 2 | 11 | Methocarbamol Heart Failure Congestive Hear… | - - | |||
| NCT01264770 2010-023692-26 Details | 2014-05-06 Interventional | 2 | 644 | Adalimumab Arthritis Arthritis, Rheu… Rheumatoid Arth… | AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to
Rigel Pharmaceuticals. - | |||
| NCT00942539 Details | 2014-05-06 Interventional | 2 | 12 | Midazolam Anxiety Pain | - - | |||
| NCT00588822 Details | 2014-05-06 Interventional | 2 | 21 | Rituximab Monoclonal Gamm… Paraproteinemia… Peripheral Nerv… Precancerous Co… Precancerous Co… | Discontinuation due to the high response rate at the 1st stage and slow accrual. The study was discontinued at the first stage to the high response rate and slow accrual. | |||
| NCT00907829 Details | 2014-05-05 Interventional | 2 | 0 | Lidocaine Stroke Cerebrovascular… | Methods unexpectedly required additional refinement that precluded subject enrollment. - | |||
| NCT00385138 Details | 2014-05-05 Interventional | 3 | [1 Refs] | 5364 | Cangrelor Clopidogrel Acute Coronary … Atherosclerosis Acute Coronary … | Insufficient evidence of the clinical effectiveness of cangrelor Discontinued per prespecified stopping rules after the 70% interim analyses was conducted indicating the trial was not likely not meet the goal of demonstrating superiority to clopidogrel administered as usual care. No safety issues were identified. | ||
| NCT01179737 NCT01531270 2010-019883-36 Details | 2014-05-01 Interventional | 2 | 23 | Nilotinib Familial Primar… Hypertension Pulmonary Arter… | Study was terminated due to serious adverse event (SAE) - | |||
| NCT00933985 Details | 2014-05-01 Interventional | 1 | 22 | Dexrazoxane Doxorubicin Liposomal doxor… Obatoclax Razoxane Vincristine Blast Crisis Burkitt Lymphom… Immunoblastic L… Intraocular Lym… Leukemia Leukemia, Hairy… Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Lymphoma Lymphoma, B-Cel… Lymphoma, Extra… Lymphoma, Large… Lymphoma, Large… Lymphoma, Large… Lymphoma, Non-H… Lymphoma, T-Cel… Lymphoma, T-Cel… Lymphoma, T-Cel… Lymphomatoid Gr… Mycoses Mycosis Fungoid… Plasmablastic L… Precursor Cell … Recurrence Sezary Syndrome Acute Leukemias… Acute Undiffere… Angioimmunoblas… Blastic Phase C… Childhood Burki… Childhood Chron… Childhood Diffu… Childhood Immun… Childhood Nasal… Cutaneous B-cel… Hepatosplenic T… Noncutaneous Ex… Peripheral T-ce… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Cutan… Recurrent Mycos… Recurrent/Refra… Refractory Chro… Refractory Hair… Relapsing Chron… Small Intestine… Unspecified Chi… | - - | |||
| NCT01110330 Details | 2014-04-29 Interventional | 3 | 583 | Ketoconazole Tinea Tinea Pedis | Unexpected discordant results between the KOH microscopy and mycological culture tests at three
study sites in the UK. The study was terminated prematurely by the sponsor due to significant discrepancies between potassium hydroxide and mycological culture results. | |||
| NCT00521989 Details | 2014-04-29 Interventional | 2 | 279 | Dipyridamole Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Osteoarthritis Osteoarthritis,… Knee Osteoarthr… | CRx-102-006 study results, negative - | |||
| NCT02016547 2012-005493-66 Details | 2014-04-25 Interventional | 4 | - | Abciximab Tissue Plasmino… Infarction Infarction, Mid… | - - | |||
| NCT01646515 Details | 2014-04-24 Interventional | 3 | 41 | Udenafil Heart Failure Heart Failure, … Systolic Murmur… Systolic Heart … | Substantial benefit was observed in the active treatment group - | |||
| NCT00819910 Details | 2014-04-24 Interventional | 4 | [2 Refs] | 41 | Fenofibrate Rosiglitazone Hyperlipidemias Hyperlipoprotei… Hypertriglyceri… Hypertriglyceri… Non Diabetic Su… | Slow recruitment and increase in deployment overseas limiting follow up First, the study was terminated early per FDA recommendations restricting rosiglitazone use. Second, recruitment of patients was slow due to deployment restraints. | ||
| NCT00593957 Details | 2014-04-23 Interventional | 2 | 38 | Dextromethorpha… Levomethorphan Rett Syndrome Syndrome | Study changed to a placebo controlled trial of dextromethorphan The trial was terminated due to the FDA requiring a placebo controlled trial instead of the ongoing open label trial. As recruitment was delayed,the total number of participants was also less than anticipated. | |||
| NCT00997087 Details | 2014-04-22 Interventional | 2 | 11 | Flumazenil Compulsive Pers… Obsessive-Compu… Obsessive Compu… | Study completed and data was inconclusive. - | |||
| NCT01737879 Details | 2014-04-21 Interventional | 4 | 41 | Epoetin Alfa Anemia | Terminated: Test article, Omontys, was recalled from the market; Enrollment has halted
prematurely and will not resume; participants are no longer being treated - | |||
| NCT01514981 Details | 2014-04-21 Interventional | 1 | 7 | Mogamulizumab Asthma | Administrative decision - |